British adults turn to the pharmacy Companies at Continue to improve COVID-19 treatments without ruling out others Conditions
New search captures British attitude towards COVID-19 treatment options
London, 06.01.2021 – Pharmaceutical companies must continue to improve COVID-19 treatments based on new variants without setting aside work in other areas of health, according to new data from YouGov and Informa Pharma Intelligence, the world’s leading provider of information to the biopharmaceutical industry.
These data, included in Informa Pharma’s “Q4 2021 Clinical Trials and the COVID-19 Landscape” report, captures UK adults’ perceptions of innovation in the pharmaceutical industry as well as attitudes towards COVID treatment options -19 current.
Three major conclusions of the report:
· Big pharmaceutical companies need more innovation – More than half of the population (55%) expect pharmaceutical and biotech companies to continue working together to continue to develop better and more effective COVID-19 treatments and preventive care, with 39% of the population believing that a better vaccination against COVID-19 will be available in the near future. However, almost a third (32%) fear COVID-19 will push researchers to put aside other key drug treatments / innovations unrelated to COVID-19.
· Britons fear Brexit is the main obstacle that could threaten access to medicines – Access to medicines has been touted as the next health crisis in the UK. The data revealed that the most cited causes of concern are Brexit / border issues (53%), shortage of truck drivers (48%), Waiting time for general practitioners (42%), backlog of NHS appointments (41%) and the continuing effects of the COVID-19 pandemic (36%). In Northern Ireland, this amounts to 69% who fear Brexit threatens access to medicines and prescription drugs.
· Awareness of the innovation process in healthcare is increasing – Many members of the general population report understanding how vaccines / treatments are developed and distributed (34%), approved (34%) and the use of clinical trials (31%) has increased since the start of the pandemic. However, the understanding of what mRNA vaccines are and how mRNA vaccines work is poor at just over a quarter. (27%) of respondents.
Daniel Chancellor, Director of Thought Leadership at Informa Pharma Intelligence, comments: “Over the past two decades, the number of treatments designed using RNA technology has slowly increased, but was not widely known outside scientific circles. The pandemic has been a game-changer, as the industry and public recognition for the new class of vaccines has increased, and the mRNA pipeline itself has tripled since 2019 to become one of the hottest areas for the development of medications.
“It is interesting that the application of mRNA technology extends to the development of treatments for diseases that have eluded scientists for some time, such as cancer or HIV, for example. While development of these is still in its infancy, highly specialized biotechnology companies are probably on the right track to produce effective vaccines against a range of new diseases. ‘
The data recognizes this progress, with half (50%) of UK adults believe COVID-19 has forced pharmaceutical companies to step up their pace of treatment innovation.
British adults’ expectations of pharmaceutical and biotech companies going forward are that they will continue to work together to accelerate the pace of innovation in other areas (such as cancer and infectious diseases) (50%) and believe they should play a bigger role in tackling vaccine inequalities (28%).
For more information on this research, the full report will soon be available online at Informa Pharma Intelligence.